April 20, 2023 – BeiGene, Novartis’ tislelizumab stages comeback with broader stomach cancer trial win

When BeiGene and Novartis announced a partial trial win for tislelizumab in stomach cancer, doubts started to circulate around the PD-1 inhibitor’s potential. Now, the partners have come back with broader success.

Tislelizumab’s ability to extend lives in newly diagnosed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma now covers all patients with or without PD-L1 expression in their tumors, BeiGene said Thursday.